117 related articles for article (PubMed ID: 38369190)
1. Unraveling the Significance of MET Focal Amplification in Lung Cancer: Integrative NGS, FISH, and IHC Investigation.
Xiang C; Lv X; Chen K; Guo L; Zhao R; Teng H; Ye M; Kuang T; Hou T; Liu C; Du H; Zhang Z; Han Y
Mod Pathol; 2024 Apr; 37(4):100451. PubMed ID: 38369190
[TBL] [Abstract][Full Text] [Related]
2. Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy.
Kron A; Scheffler M; Heydt C; Ruge L; Schaepers C; Eisert AK; Merkelbach-Bruse S; Riedel R; Nogova L; Fischer RN; Michels S; Abdulla DSY; Koleczko S; Fassunke J; Schultheis AM; Kron F; Ueckeroth F; Wessling G; Sueptitz J; Beckers F; Braess J; Panse J; Grohé C; Hamm M; Kabitz HJ; Kambartel K; Kaminsky B; Krueger S; Schulte C; Lorenz J; Lorenzen J; Meister W; Meyer A; Kappes J; Reinmuth N; Schaaf B; Schulte W; Serke M; Buettner R; Wolf J
J Thorac Oncol; 2021 Apr; 16(4):572-582. PubMed ID: 33309988
[TBL] [Abstract][Full Text] [Related]
3. MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.
Guo R; Berry LD; Aisner DL; Sheren J; Boyle T; Bunn PA; Johnson BE; Kwiatkowski DJ; Drilon A; Sholl LM; Kris MG
J Thorac Oncol; 2019 Sep; 14(9):1666-1671. PubMed ID: 31228623
[TBL] [Abstract][Full Text] [Related]
4. Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer.
Pelosi G; Gasparini P; Conte D; Fabbri A; Perrone F; Tamborini E; Pupa SM; Ciravolo V; Caserini R; Rossi G; Cavazza A; Papotti M; Nakatani Y; Maisonneuve P; Pastorino U; Sozzi G
J Thorac Oncol; 2016 May; 11(5):718-728. PubMed ID: 26804638
[TBL] [Abstract][Full Text] [Related]
5. Detection of
Sun B; Qiu T; Zeng X; Duan J; Bai H; Xu J; Li J; Li J; Hao X; Liu Y; Lin L; Wang H; Zhang X; Zhong J; Wang J; Ying J; Wang Z
Cancer Res Commun; 2023 Apr; 3(4):532-539. PubMed ID: 37025355
[TBL] [Abstract][Full Text] [Related]
6. Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases.
Tran TN; Selinger CI; Kohonen-Corish MR; McCaughan B; Kennedy C; O'Toole SA; Cooper WA
Clin Lung Cancer; 2016 Jan; 17(1):30-8.e1. PubMed ID: 26395411
[TBL] [Abstract][Full Text] [Related]
7. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Lai GGY; Lim TH; Lim J; Liew PJR; Kwang XL; Nahar R; Aung ZW; Takano A; Lee YY; Lau DPX; Tan GS; Tan SH; Tan WL; Ang MK; Toh CK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Yuan J; Lim TKH; Lim AST; Hillmer AM; Lim WT; Iyer NG; Tam WL; Zhai W; Tan EH; Tan DSW
J Clin Oncol; 2019 Apr; 37(11):876-884. PubMed ID: 30676858
[TBL] [Abstract][Full Text] [Related]
8. Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysis.
Zhao S; Ma Y; Liu L; Fang J; Ma H; Feng G; Xie B; Zeng S; Chang J; Ren J; Zhang Y; Xi N; Zhuang Y; Jiang Y; Zhang Q; Kang N; Zhang L; Zhao H
Lung Cancer; 2024 Feb; 188():107468. PubMed ID: 38181454
[TBL] [Abstract][Full Text] [Related]
9. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
[TBL] [Abstract][Full Text] [Related]
10. Non-small cell lung cancer with
Yang M; Mandal E; Liu FX; O'Hara RM; Lesher B; Sanborn RE
Front Oncol; 2023; 13():1241402. PubMed ID: 38273845
[TBL] [Abstract][Full Text] [Related]
11. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.
Tong JH; Yeung SF; Chan AW; Chung LY; Chau SL; Lung RW; Tong CY; Chow C; Tin EK; Yu YH; Li H; Pan Y; Chak WP; Ng CS; Mok TS; To KF
Clin Cancer Res; 2016 Jun; 22(12):3048-56. PubMed ID: 26847053
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp- untreated patients with advanced non-small cell lung cancer.
Peng KC; Su JW; Xie Z; Wang HM; Fang MM; Li WF; Chen YQ; Guan XH; Su J; Yan HH; Zhang XC; Tu HY; Zhou Q; Chen HJ; Wu YL; Yang JJ
Thorac Cancer; 2022 Jun; 13(11):1619-1630. PubMed ID: 35437920
[TBL] [Abstract][Full Text] [Related]
13. c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas.
Mignard X; Ruppert AM; Antoine M; Vasseur J; Girard N; Mazières J; Moro-Sibilot D; Fallet V; Rabbe N; Thivolet-Bejui F; Rouquette I; Lantuejoul S; Cortot A; Saffroy R; Cadranel J; Lemoine A; Wislez M
J Thorac Oncol; 2018 Dec; 13(12):1962-1967. PubMed ID: 30149144
[TBL] [Abstract][Full Text] [Related]
14. MET amplification, protein expression, and mutations in pulmonary adenocarcinoma.
Park S; Koh J; Kim DW; Kim M; Keam B; Kim TM; Jeon YK; Chung DH; Heo DS
Lung Cancer; 2015 Dec; 90(3):381-7. PubMed ID: 26791796
[TBL] [Abstract][Full Text] [Related]
15. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.
Saigi M; McLeer-Florin A; Pros E; Nadal E; Brambilla E; Sanchez-Cespedes M
Clin Transl Oncol; 2018 Jul; 20(7):881-888. PubMed ID: 29139039
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies.
Castiglione R; Alidousty C; Holz B; Wagener S; Baar T; Heydt C; Binot E; Zupp S; Kron A; Wolf J; Merkelbach-Bruse S; Reinhardt HC; Buettner R; Schultheis AM
Mod Pathol; 2019 May; 32(5):627-638. PubMed ID: 30459450
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological characteristics of Non-Small Cell Lung Cancer (NSCLC) patients with c-MET exon 14 skipping mutation, MET overexpression and amplification.
Ding C; Qiu Y; Zhang J; Wei W; Gao H; Yuan Y; Wang X
BMC Pulm Med; 2023 Jul; 23(1):240. PubMed ID: 37400762
[TBL] [Abstract][Full Text] [Related]
18. Activity of Tepotinib in Hepatocellular Carcinoma With High-Level
Qin S; Pan H; Blanc JF; Grando V; Lim HY; Chang XY; O'Brate A; Stroh C; Friese-Hamim M; Albers J; Johne A; Faivre S
JCO Precis Oncol; 2024 Feb; 8():e2300328. PubMed ID: 38354329
[TBL] [Abstract][Full Text] [Related]
19. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.
Jurmeister P; Lenze D; Berg E; Mende S; Schäper F; Kellner U; Herbst H; Sers C; Budczies J; Dietel M; Hummel M; von Laffert M
Lung Cancer; 2015 Feb; 87(2):122-9. PubMed ID: 25534130
[TBL] [Abstract][Full Text] [Related]
20. MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.
Dagogo-Jack I; Yoda S; Lennerz JK; Langenbucher A; Lin JJ; Rooney MM; Prutisto-Chang K; Oh A; Adams NA; Yeap BY; Chin E; Do A; Marble HD; Stevens SE; Digumarthy SR; Saxena A; Nagy RJ; Benes CH; Azzoli CG; Lawrence MS; Gainor JF; Shaw AT; Hata AN
Clin Cancer Res; 2020 Jun; 26(11):2535-2545. PubMed ID: 32086345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]